Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMOX plus nab-paclitaxel in advanced biliary tract cancer
NCT03943043Phase 2Unknown
- Sponsor
- Humanitas Research Hospital
- Start
- Jul 2017
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in biliary tract cancer (BTC), sponsored by Humanitas Research Hospital. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Status: unknown.
02
Drugs
paclitaxel
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03943043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03943043.